支气管哮喘、慢阻肺患者应用白三烯受体拮抗剂的疗效观察

目的：探讨白三烯受体拮抗剂治疗支气管哮喘、慢阻肺（COPD）患者的疗效。方法：选择上述疾病各20例患者，服用 同样测量安可来，观察治疗前后以血中白三烯C4、嗜伊红细胞、肺功能PET数值变化，判断疗效。结果：哮喘组治疗前血中LTC4、EOS浓度高于正常，PEF低于正常。治疗，血中LTC4、EOS浓度下降，肺功能PEF上升（P＜0．01）。COPD组发作期治疗前血中LTC4、EOS浓度高于正常，肺功能PEF低于正常。治疗后LTC4、EOS血中浓度无明显变化，PEF无明显上升（P＞0．05），两组间疗效比较差异有显著性（P＜0．01）。结论：哮喘与COPD由于发病机理不同，对白三烯体拮抗剂的疗效也不同，因灰哮喘是涉及气道一系列炎性细胞和介质复杂的病理过程，白三烯是主要介质之一。

Therapeutic Effect of Leukotriene Receptor Antagonist for Bronchial Asthma and COPD

To observe the curative effect of leukotriene receptor antagonist on bronchial asthma and chronic obstructive pulmonary disease (COPD). Methods: Twenty patients with bronchial asthma and 20 with GOPD were studied. Accolate was administrated with the same dosage. The curative effect was determined according to the changes of leukotriene C4, eosinocyte, and PEF of pulmonary function before and after treatment. Results: The concentrations of LTC4 and EOS in plasma were higher and PEF of pulmonary function was lower than normal level in asthma group before treatment. The concentrations of LTC4 and EOS in plasma significantly decreased and the value of PEF significantly increased after treatment (P<0.01). The levels of LTC4 and EOS in plasma were higher and PEF of pulmonary function was lower than normal level at attacking stage in COPD group before treatment. There was no significant change in LTC4 and EOS, and no significant increase in PEF after the treatment (P >0.05). There was a significant difference in LTC4 , EOS, and PEF between two groups before and after the treatment (P<0.01). Conclusion: The curative effect of leukotriene receptor antagonist is different for the cause of different pathogenesis. Asthma is a complicated course involved by a serious of inflammatory cells and media. Leukotriene is one of the main media.